Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme

OBJECTIVE: Longitudinal clinical registry-infrastructures such as Anti-Rheumatic Therapies in Sweden (ARTIS) allow simultaneous comparison of the safety of individual immunomodulatory drugs used in clinical practice, with consistent definitions of treatment cohorts, follow-up and outcomes. Our objec...

Descripción completa

Detalles Bibliográficos
Autores principales: Frisell, Thomas, Bower, Hannah, Morin, Matilda, Baecklund, Eva, Di Giuseppe, Daniela, Delcoigne, Benedicte, Feltelius, Nils, Forsblad-d'Elia, Helena, Lindqvist, Elisabet, Lindström, Ulf, Askling, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176333/
https://www.ncbi.nlm.nih.gov/pubmed/36787994
http://dx.doi.org/10.1136/ard-2022-223762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176333/
https://www.ncbi.nlm.nih.gov/pubmed/36787994
http://dx.doi.org/10.1136/ard-2022-223762

Ejemplares similares